CTX-471 trial terminated after combo arm misses efficacy; two device trials await start

Three registry filings surfaced this week, one with posted results and two newly listed studies awaiting enrollment.

• Compass Therapeutics' Phase 1 study of CTX-471, alone or with pembrolizumab, in patients with metastatic or locally advanced cancers who had inadequate responses to PD-1/PD-L1 inhibitors has an overall status of terminated, with the reason given that the combination therapy arm with pembrolizumab did not yield an efficacy signal, so enrollment into that arm was stopped¹. The monotherapy arm of the study was fully enrolled and completed¹, and results were first posted 2026-10-09.
• Boston Scientific's "ODYSSEY" study of its Y-90 glioblastoma device in recurrent GBM is not yet recruiting, with an estimated start of 2026-10-01. The trial is a dose-escalation study designed to determine the safest and most appropriate radiation dose, with planned doses ranging from 60 Gy to 120 Gy, starting at 60 Gy with increases of 20 Gy for subsequent patient groups²; enrollment is estimated at 30 participants.
• SpinaFX Medical's "RELIEF" study of the Triojection® System for lumbar radiculopathy from a contained herniated disc is not yet recruiting, with an estimated start of 2027-01-15. The trial will randomize participants 1:1 to either Triojection® System followed by Selective Nerve Root Block or SNRB alone³, with planned enrollment of up to 300 participants at up to 30 investigational sites in the United States and Canada³.